Original Research

General Short-Term Indomethacin Prophylaxis to Prevent Heterotopic Ossification in Total Hip Arthroplasty

S. Hofmann, MD*  
H.-J. Trnka, MD†  
H. Metzenroth, MD†  
E. Frank, MD‡  
P. Ritschl, MD†  
M. Salzer, MD‡

ABSTRACT

This prospective study evaluated heterotopic ossification prophylaxis with indomethacin for 14 days in 201 consecutive patients undergoing total hip arthroplasty. Ranitidine was administered concurrently to alleviate gastrointestinal side effects. None of the patients with mild gastrointestinal side effects (12%) had to suspend the prophylaxis, and no major postoperative bleeding or gastrointestinal ulcers were observed. After 12 months of follow-up, 67% of patients had no evidence of heterotopic ossification, 32% percent had grades I and 1% had grade III without clinical significance, and 0% had grade IV ossification according to Brooker's classification. These results indicate that short-term indomethacin prophylaxis is an effective, inexpensive, and easily administrated alternative to single-dose radiotherapy for nearly all patients undergoing THA.

The development of heterotopic ossification following total hip arthroplasty (THA) is a well-documented complication that might interfere with patient outcome. The incidence of total heterotopic ossification ranges from 8% to 90%, and the incidence of clinically significant lesions has been reported to range from 1% to 24%. Pain and decreased range of motion are the common limiting factors for the patient and can even cause virtual ankylosis of the hip joint.

Various efforts to prevent heterotopic ossification have been undertaken in the past. Local radiation and anti-inflammatory medication are the two established and effective treatment modalities to prevent heterotopic ossification after THA.

Indomethacin is the most common prophylactic drug and has been thoroughly investigated regarding its efficiency. Increased postoperative bleeding, dyspepsia, gastric ulcer, renal dysfunction, and cerebral confusion are short-term side effects, while reduced bony ingrowth in the prosthesis or nonunion of a trochanter osteotomy have been described as late-term side effects related to indomethacin.

Single-dose irradiation is the most common radiotherapeutic prophylaxis to prevent heterotopic ossification, and its efficiency has been well-documented. Nevertheless, there are logistical problems, a risk for reduced bony ingrowth, and a probable risk of sarcoma.

Because of the side effects of anti-inflammatory medication and the disadvantages of local irradiation, until recently heterotopic ossification prophylaxis was only recommended for patients at risk for heterotopic ossification. Since the development of heterotopic ossification cannot be reliably predicted before surgery in most cases, the indications for prophylaxis still remain unclear.

This study investigated the practicability, efficiency, and side effects of general heterotopic ossification prophylaxis with indomethacin in THA.

MATERIALS AND METHODS

For a period of 6 months, 201 consecutive THA patients (143 women and 58 men) scheduled for THA were included in a prospective study. Mean patient age was 68.3 years (range: 32-97 years). Different surgical proce-
(4%) cases had heterotopic ossification progressed one grade between the 3- and 12-month follow-up evaluations. Range of motion was not limited in any of the patients with grade I, II, or III heterotopic ossification nor did any of the patients complain of pain related to heterotopic ossification.

An avulsion of the tip of the trochanter major was observed on the immediate postoperative radiograph in 36 (18%) cases. In 12 of these patients, an apparent grade I heterotopic ossification and in 1 case an apparent grade III heterotopic ossification had developed at follow-up (Fig 2), but these cases were not counted as heterotopic ossification.

Of the 144 patients with uncremented primary THAs, 14 (10%) were lost to follow-up at the 24-month evaluation (9 had died, 2 had moved, and 3 could not be located). The average follow-up of the remaining 130 patients was 39 months (range: 24-68 months). None of these patients presented with clinical or radiographic signs for aseptic loosening of the femoral prosthetic component at the final follow-up.

**Discussion**

The efficacy of anti-inflammatory heterotopic ossification prophylaxis is generally accepted, but there is still controversy about the duration of prophylaxis. Several authors advocate the use of anti-inflammatory drugs for a period of 3 up to 12 weeks. In recent studies, short-term prophylaxis from 7 to 14 days has shown to have a convincing ability to decrease heterotopic ossification, whereas administration for only 4 days could not achieve an acceptable prevention of heterotopic ossification.

Due to the side effects of anti-inflammatory medication, most of the studies to date have recommended prophylaxis only for patients at risk for heterotopic ossification. However, among the extensive literature dealing with heterotopic ossification after THA, no report has clearly shown how to predict which patients are at risk. Therefore, until recently, many patients without evident risk factors were not treated, and some of these patients developed heterotopic ossification.

Based on our own experience with anti-inflammatory heterotopic ossification prophylaxis, we have routinely used indomethacin prophylaxis since 1987 for every THA we performed. In this study, anti-inflammatory medication was proven to be an inexpensive and easily administered heterotopic ossification prophylaxis for nearly all of the patients undergoing THA. Only 1% of the patients had to be excluded preoperatively, and an additional 1% did not receive the prophylaxis due to organization failures. The reasons for interrupting the prophylaxis in 4% were not indomethacin-related, and therefore 94% of the patients successfully finished the prophylaxis.

Our results are comparable to indomethacin prophylaxis for 6 weeks or a single-dose radiotherapy. It still remains unclear which minimum dosage of indomethacin may be sufficient, and therefore the risk of side effects might be further minimized by lower doses of anti-inflammatory drugs. Interestingly, in this study we found that an avulsion of the trochanter major might be misinterpreted as heterotopic ossification if the immediate postoperative radiographs are not analyzed carefully. The relatively high incidence of trochanter major avulsions in our series induced us to change our surgical technique.

In previous reports, indomethacin prophylaxis had to be interrupted in 20% to 30% of patients due to gastrointestinal irritation. The effectiveness of ranitidine or sucralfate to prevent severe gastrointestinal side effects of indomethacin prophylaxis has been proven by our group in a previous study using gastrosopic evaluation pre- and postoperatively. In this study, using ranitidine for gastric protection, only 12% of patients experi-
<table>
<thead>
<tr>
<th>Procedure</th>
<th>Primary THA</th>
<th>Revision THA</th>
<th>Total THA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncemented</td>
<td>144</td>
<td>15</td>
<td>159</td>
</tr>
<tr>
<td>Hybrid</td>
<td>23</td>
<td>4</td>
<td>27</td>
</tr>
<tr>
<td>Cemented</td>
<td>8</td>
<td>7</td>
<td>15</td>
</tr>
<tr>
<td>Total</td>
<td>175</td>
<td>26</td>
<td>201</td>
</tr>
</tbody>
</table>

TABLE

Surgical procedures

- grade I—islands of bone formation,
- grade II—heterotropic ossification from the pelvis and the proximal part of the femur, with at least 1 cm of uninvolved tissue in between,
- grade III—projections of heterotropic ossification from the pelvis and the proximal part of the femur, with <1 cm of uninvolved tissue in between, and
- grade IV—apparent ankylosis.

Clinical assessment focused on pain and stiffness as signs for heterotropic ossification around the hip.

To evaluate the effect of indomethacin on the osteointegration of cementless femoral prostheses, the 144 patients with un cemented primary THAs were examined clinically and their radiographs analyzed for signs of aseptic loosening (subidence, migration, and radiolucencies) of the femoral component at least 24 months after surgery.

RESULTS

No patient had an absolute contraindication such as indomethacin intolerance or active gastric ulcer, but 2 patients with relative contraindications had to be excluded from the study at the time of surgery. Eighteen (9%) patients with preexisting heterotropic ossification were considered at high risk for heterotropic ossification (Fig 1), while 87 (44%) patients had one or more heterotropic ossification low risk factor (male gender [58 patients], hypertrophic osteoarthritis [27 patients], concentric osteoarthritis [16 patients], and revision THA [26 patients]).

The two patients who did not receive no indomethacin were original-ly included in the study, but due to organization failure at the ward, they did not receive their medication. Seven (4%) patients interrupted the protocol for non-indomethacin-related problems (4 for renal insufficiency, 1 for unclear allergy symptoms of the skin, 1 for cardial decompensation, and 1 for diarrhea). These 9 patients were excluded from the study.

Two patients interrupted the prophylaxis for <3 days but were not excluded from the study. Twenty-four (12%) patients complained of mild side effects (gastric problems or cerebral confusion) but did not interrupt the prophylaxis. Therefore, a total of 190 (93%) patients finished the indomethacin prophylaxis successfully. No severe increased postoperative bleeding or gastrointestinal ulcers were observed during patients' hospital stay.

At 1 year postsurgery, 10 (7%) patients were lost to follow-up (4 patients had died and 6 could not be located). Out of the 180 patients available for the 1-year follow-up evaluation, 120 (67%) patients had grade 0, 55 (31%) patients had grade I, 3 (1%) patients had grade II, and 2 (1%) patients had grade III ossification according to Brooker's classification. No patient developed grade IV heterotropic ossification.

All of the heterotropic ossifications were visible at 3 month, and in only 8
enced mild gastrointestinal side effects. After explaining the necessity of the prophylaxis to the patients, these side effects were tolerated, and no patient interrupted the prophylaxis.

Increased postoperative bleeding may be another short-term side effect of indomethacin. The antithrombotic effect of anti-inflammatory drugs combined with low-dose heparin has not been shown to increase postoperative bleeding in clinical trials.

In a recent report, the combination of indomethacin and warfarin caused no significant differences in the average maximum prothrombin time or bleeding complications in THA when compared with a matched-pair control group with warfarin only. Although we did not observe any severe increase in postoperative bleeding, this possible side effect was not especially evaluated in this study.

Inhibition of bony ingrowth for uncemented THA and nonunion of trochanter osteotomy are long-term side effects of indomethacin prophylaxis. Inhibition of new bone formation has been shown to be dose-dependent.

In our trial, using 50 mg indomethacin twice daily for 14 days, no clinical or radiographic signs of aseptic loosening after primary uncemented THA were found with a minimum of 24 months of follow-up. This finding is supported by our clinical experience in more than 2500 cases of uncemented THA in which this standard protocol was routinely used. Nevertheless, the clinical significance of bony ingrowth inhibition by indomethacin in cementless THA can only be determined by a randomized, placebo controlled study with long-term follow-up.

**CONCLUSION**

Short-term indomethacin prophylaxis is an effective, inexpensive, and easily administrated therapy to prevent heterotopic ossification. Based on our experience with anti-inflammatory prophylaxis since 1987, general short-term indomethacin heterotopic ossification prophylaxis combined with gastric protection is a sufficient and safe method for nearly all patients undergoing THA.

**REFERENCES**

32. Wise MV III, Robertson ID, Luchiewicz PF, Threl DL, Metcalfe M. The effect of radiation therapy on the fixation strength of an experimen-


